Category: Covid-19 Vaccine

Page 262«..1020..261262263264..270280..»

COVID-19 vaccine requirement for children explored by State Board of Health April 13 – Washington Policy

March 31, 2022

Washingtons State Board of Health plans to go over a recommendation againstincluding a COVID-19 vaccination requirement for school entry at its all-day meeting April 13. Petitions concerning the decision-making about such a requirement also will be introduced, and time for public comment is included on the meetingsdraft agendareleased today.

Action by the board on these issues is possible.

Even though the technical advisory group set up by the states Department of Health and the State Board of Health (SBOH) advised against a COVID-19 vaccine requirement for school children, the issue is listed on the draft agenda this way: Briefing Recommendations from the Technical Advisory Group (TAG) to consider COVID-19 for Inclusion inWAC 246-105-030 Possible Action. That could mean the board will be considering more than just the majority decision of the group. Several TAG members did want the vaccine included on the vaccination schedule or weretorn about the timing of such a requirement.

The board has the final say on the matter, not the advisorygroup. However, the board saysthat it usually goes along with the formal recommendations it receives.

Not enough is known yet about the vaccine and its side effects, advisory group members said in their considerations, and the requirement felt out of line when theshots given for COVID-19 do not prevent transmission of the virus.

Lack of disease prevention makes this whole exercise of considering the inclusion of a COVID-19 vaccine questionable. TheWashington Administrative Codeoutlining school-entry requirements is titled, Immunization of child care and school children against certain vaccine-preventable diseases. COVID-19 is not a vaccine-preventable disease. Other, long-proven vaccines on the requirement list are well-demonstrated in prevention and an essential part of public health.

Submitting public commentfor or against the idea of COVID-19 vaccination inclusion is easy, as is registering to attend the online meeting or signing up to givecomments verbally. Instructions are on the SBOHsmeeting information page. (Know that written comments are due by noon on April 8.)

Washington Policy Center is hopeful that parents, in consultation with their childrens doctors, will remain in charge of determining whether a COVID-19 shot is best for a child without the pressure of a school-entry requirement. The advisorygroup the SBOH convenedwas right inrecommendingagainst the idea, given what we know about COVID-19 and vaccinerisks, as well as theprevention limitations of the vaccines.

More:

COVID-19 vaccine requirement for children explored by State Board of Health April 13 - Washington Policy

We want our kids vaccinated — but we can’t rush the process – CNN

March 31, 2022

As mothers who are also public health professionals, we follow the data. We've read extensively about the safety and efficacy of the adult Covid-19 mRNA vaccines from Pfizer/BioNTech and Moderna. And now we are reading Moderna's news releases carefully, trying to piece together how quickly the company might submit a request to the US Food and Drug Administration for emergency use authorization for young kids. ("In the coming weeks," said Moderna.) Following the data has given us confidence in the vaccine's safety, and we both have tried to enroll our kids in vaccine trials (one of us succeeded with enrollment in the Moderna trial). And now, our families, like so many others, are awaiting news from the Moderna and Pfizer vaccine trials for babies, toddlers and preschoolers.We want a vaccine for our kids, especially now that many people are unmasking and a subvariant is threatening a new surge. But we know waiting for the FDA's stamp of approval is a critical part of the process; when a vaccine is available for our young kids, we will rest assured that it has been thoroughly vetted. In February, we found ourselves in a similar situation, on what seemed like the brink of FDA authorization for the Pfizer vaccine for kids 6 months through 4 years of age. But just as FDA scientists were poised to convene a public meeting to discuss authorization, they decided to delay their review until Pfizer could provide data from a third dose. Our dreams that our kids could get vaccinated as Omicron surged were dashed. Although frustrating, this underscored the scientific rigor and caution of vaccine trials and oversight. There are never shortcuts -- not even when we wish they would move quickly.

We'll know more about Moderna's trial data when the company applies for emergency use authorization. But what little we know seems hopeful: Last week's news release shared that kids 6 months through 5 years of age had similar immune responses to the 25 micrograms pediatric dosages as adults who also received two doses of the 100 micrograms adult dosage. The vaccine's protection against infection was also similar for the kids in the trial compared with adults who received two doses during the same time period when Omicron was dominant.

When we know more about the trial data, we'll be comparing what we know about the vaccine with what we know about Covid-19's risks for our kids, families and communities.

Nearly all kids are also just a few degrees of separation from someone at high risk, whether close connections (like friends, teachers or grandparents) or more distant connections (like friends of friends). Vaccinating kids of all ages can help to protect those of us who are especially vulnerable by breaking transmission chains and reducing the amount of virus circulating in the community. This enables all of us to get back to doing the things we love.

We invite others to join us in listening to the public meetings to learn more about the safety and efficacy of the Covid-19 vaccines for young kids. Scientists leading the trials will discuss their results and answer questions from the committees of experts who will review the data and make recommendations.

And until we're able to vaccinate them, we'll continue to use the proven tools that we know can keep our young kids safe: vaccinating those around them, making indoor air safer, masking, staying home when sick and testing. We can't wait to add vaccination to the tools accessible to our young kids.

We're hopeful the wait isn't much longer.

See the original post:

We want our kids vaccinated -- but we can't rush the process - CNN

CureVac and Glaxo Begin Testing New ‘Second Generation’ Covid-19 Vaccine – Barron’s

March 31, 2022

CureVac and GlaxoSmithKline said Wednesday that they had dosed the first patient in the first trial of what they call their second-generation messenger RNA vaccine for Covid-19.

The companies said that the development program to test the vaccine, known as CV2CoV, will serve as a proof of concept not just for the vaccine itself, but for CureVacs (ticker: CVAC) updated mRNA technology.

CureVac...

Go here to read the rest:

CureVac and Glaxo Begin Testing New 'Second Generation' Covid-19 Vaccine - Barron's

JCDHE to offer second booster doses to certain populations – JoCoGov.org

March 31, 2022

On March 31, Johnson County Department of Health and Environment will begin administering second booster doses of COVID-19 to those who are eligible.

The U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and the Kansas Department of Health and Environment have endorsed a second booster with the following requirements for eligibility:

JCDHE will begin offering second boosters on March 31 to those who are eligible at its Mission COVID-19 vaccination clinic, located at 6000 Lamar Ave. Clinic hours are 8 a.m. to 3 p.m. on a walk-in, first come, first served basis. Starting April 5, the Mission clinic will be open on a walk-in basis on Tuesdays only from 1-6:30 p.m.

Boosters are also available at other providers, including physician offices, pharmacies and grocery stores or by visiting https://www.vaccines.gov/.

COVID-19 boosters strengthen the protection against severe outcomes from COVID-19. As we have seen with Omicron and other SARS-CoV-2 variants, the risk from COVID-19 continues.The vaccines are safe and effective, and we urge all those who are eligible to receive their first, second or booster doses said Sanmi Areola, PhD, JCDHE director.

Those with questions about booster shots can call 913-715-2819 from 8 a.m. to 5 p.m., Monday through Friday. They can also send an email to [emailprotected]. Emails are answered 8 a.m. to 5 p.m., Monday through Friday. Spanish speakers will be available to answer calls or emails.

View post:

JCDHE to offer second booster doses to certain populations - JoCoGov.org

A Covid-19 spike like the one in China is unlikely in the US, experts say. Here’s why – CNN

March 31, 2022

CNN

The Omicron coronavirus variant may be reaching around the world, but different places are seeing significantly different effects.

In the United States, Covid-19 case numbers have been falling since January. They may have hit a plateau as a subvariant of Omicron, BA.2, becomes the main cause of infections.

But in China, an area of the world that has had few spikes during the pandemic, there has been a dramatic increase in cases as BA.2 rips through the country.

The difference, experts say, is part policy and part population-level immunity. Whats happening in China doesnt necessarily mean the US is in for another huge spike in cases.

Public health is very much a local thing, said Andy Pekosz, a virologist at the Johns Hopkins School of Public Health.

With the first Covid-19 cases in 2020, he said, trends were similar around the globe because most peoples bodies had no experience with the coronavirus, and there were no vaccines. They had no protection against it.

Since then, different countries have used different vaccines and have had different success with vaccination campaigns. Theres also a different level of immunity among populations in different regions. All of that affects the trajectory of Covid-19 cases.

You would probably expect to see more variation from country to country in terms of case numbers and surges and fatality rates from here on out, Pekosz said. All of that means its just difficult to make blanket statements about how things are going to go forward.

Lockdowns in the US are a thing of the past and will probably stay that way, public health experts say. Though the decline in case numbers seems to be leveling off in the US, its rare to see someone wearing a face mask in many places.

By comparison, China has a zero-Covid policy. As cases have been on the rise in more than two dozen provinces, restrictions have gotten much tougher.

In Shanghai, a city of 26 million, people are confined to their homes, able to go out only for essential supplies. Regular tests are mandatory. Officials throughout China check color-based health code systems to monitor peoples movements. Everyone has a smartphone app that shows their personal QR health code: green for healthy, yellow for close contacts and red for confirmed or suspected cases.

If someone tests positive for Covid-19 even if they dont have symptoms they must isolate in large temporary facilities set up in stadiums and convention centers. They cant leave until they test negative twice. Pets are even sent to other centers for monitoring. Public health officials cordon off the persons home and disinfected everything.

With the highly contagious Omicron variant, lockdowns cant totally stop the growth in cases, but the strategy has helped, experts say.

Chinas seven-day daily new case average is more than 14,000, according to Johns Hopkins University. By way of comparison, the country has about four times as many people as the US but as of Thursday, the US is averaging more than 30,000 new Covid-19 cases per day. This is one of the lowest daily case rates since mid-July.

Thats a stark contrast, said Abram Wagner, a research assistant professor of epidemiology at the University of Michigan. Were in different trajectories, with the US case numbers going down and kind of plateauing at this point in time, so the direction is different. But I think seeing the smaller number of cases in China, I think the policies that China has in play with restrictions on some level have had an effect.

Whether strict lockdowns are too heavy-handed and infringe too much on personal liberties is a different conversation, he said. But China has kept cases much lower overall than in the US, even during a spike.

Whats made things more difficult is exactly how easy it is to catch Covid with Omicron.

Omicron has changed the equation in China, Wagner said. Its just hard to maintain a dynamic zero-Covid policy that stamps it out completely.

Omicron, to compare it to other variants before it, has really changed an awful lot of the playing field, Pekosz said. Its transmissibility is just off the charts.

Omicron is three times as likely to spread as the Delta variant. None of the vaccines made to protect against the original strain works as well, especially in populations in China that havent seen spikes over the past two years.

Sort of their firewall has broken down with Omicron, and they have a massive amount of people who are susceptible to this virus, said Justin Lessler, an epidemiologist at the University of North Carolinas Gillings School of Global Public Health.

BA.2, which is playing a role in the spike in cases in China and is now the dominant strain in the US, is especially contagious. Some epidemiologists have said BA.2s basic reproduction number may be as high as 12, meaning each sick person can infect an average of 12 others. That puts it on par with measles.

Though its difficult to predict the trajectory of the pandemic in the US, Lessler said, community immunity could keep the country from seeing an across-the-board spike. Instead, we should see a mild blip.

I expect to see some resurgence here, but its a very different picture, even with the increase in the Omicron subvariant BA.2, Lessler said.

The US population has built up immunity that China does not have. China has seen relatively few cases over the course of the pandemic, but the US Centers for Disease Control and Prevention estimates that 37 million Americans about 1 in 11 got Covid-19 in the past winter alone.

The [BA.2] subvariant of Omicron is not an entire leap ahead of Omicron, whereas Omicron was really quite different than Delta, said Dr. Davidson Hammer, a professor of global health and medicine at Boston University. I think that there are a lot of people, at least the United States, that have had Omicron, and theres growing evidence that theres theyre close enough in terms of their immunologic profile that if youve had 1, youre unlikely to get 2.

In other words, theres a more limited pool of people who might become infected in the US than in China.

Many in the US have some coronavirus immunity from vaccination and boosters. More than 81% of the population has at least some protection with at least one dose, according to the CDC. Boosters have been less popular, but they do work when people get them.

Another problem for China may be the kind of vaccines its used, according to Dr. Ian Lipkin, a professor of epidemiology at the Mailman School of Public Health at Columbia University.

The increase in the number of cases reflects a combination of factors. Your population thats immunologically naive, they havent seen much of the virus in the past and because they havent been vaccinated effectively to resist them, Likpkin said.

China has mostly used the Chinese-made Sinovac and Sinopharm vaccines. Both companies said their vaccines were more than 78% effective against Covid-19, but studies suggested otherwise. Late-stage trials of the Sinovac candidate in Brazil showed an efficacy rate of 50.38%, barely above the World Health Organization threshold for approval.

Other studies have suggested that immunity from two doses of these vaccines wanes rapidly and that the protection may be limited, especially among older people and especially compared with mRNA vaccines used in the US. And against Omicron, all vaccines have been found to offer less protection.

Wagner thinks the difference between US and Chinese vaccines may be more of a wash when it comes to Omicron, but Lipkin says he has been telling colleagues in China for months that they need better protection.

A way out of the surge would be to rapidly vaccinate everyone with more effective vaccines. Thats not what theyre doing, Lipkin said. The notion that you can somehow conquer this with lockdowns is not going to work unless youve coupled the lockdown with an effective vaccine strategy.

Its so disheartening and worrisome, he added. I spend enormous amounts of time in China, and Ive been advising them to switch vaccines for many months, and they just wont do it.

The US has done a pretty good job of vaccinating the elderly, who are more vulnerable to severe disease and death, Lessler said. Almost 90% of people 65 and older have gotten two doses of the vaccine, according to the CDC, and 70% have gotten a booster.

In China, my understanding is, the vaccine rates are sort of inverted somewhat, and the elderly have lower vaccination rates, he said.

With the most at-risk population unprotected in parts of China, Hong Kong has seen the worlds highest death rate by population size this month.

In the US this week, the Biden administration expanded eligibility for second boosters to people who are 50 and older, but one element that could limit this strategy is money. Congress failed to pass legislation that would fund Covid efforts. The uninsured may lose access to free treatments, tests and vaccines, and that could affect case numbers and deaths in the US.

With so many people getting sick globally, what also could change the direction of the pandemic in the US is another variant. If more people get sick, theres more of a chance that another strain could come along one that escapes the protection of current vaccines and treatments.

A new variant could certainly come along in the future that will bring another wave, and we will be forced to respond, Lessler said. Thats why it still makes sense to get vaccinated and boosted.

Read the original here:

A Covid-19 spike like the one in China is unlikely in the US, experts say. Here's why - CNN

FILE PHOTO: Coronavirus disease (COVID-19) vaccine booster, at the First African Episcopal Church in Los Angeles, California – The Denver Gazette

March 31, 2022

FILE PHOTO: A health care administer gives the second dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine to a person at the L.A. Care Health Plan free testing and vaccination site at the First African Episcopal Church in Los Angeles, California, U.S., January 29, 2022. REUTERS/Shannon Stapleton/File Photo

Read more:

FILE PHOTO: Coronavirus disease (COVID-19) vaccine booster, at the First African Episcopal Church in Los Angeles, California - The Denver Gazette

COVID-19 vaccine continues to be offered at weekly clinics – oswegocountynewsnow.com

March 29, 2022

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

View post:

COVID-19 vaccine continues to be offered at weekly clinics - oswegocountynewsnow.com

COVID: Do J&J vaccine recipients need a second booster? Doctors and CDC have different opinions – Vallejo Times-Herald

March 29, 2022

Drug giants Pfizer and Moderna makers of the countrys most widely used vaccines in the fight against COVID-19 are now seeking approval for a second booster shot as immunity wanes and more contagious variants come ashore. Good news for some.

But now many of the nearly 17 million Americans like Brian King who got the Johnson & Johnson jabare wondering, What about us?

I understand that were a minority share of vaccinated people, said King of Redwood City, who had the J&J shot and a Moderna booster. But seeing stories that only discuss the effectiveness of the more common vaccines leaves me with less information than Id like about such an important public health issue.

In the early rush to develop vaccines to combat the deadly coronavirus, Johnson & Johnsons one-shot contribution was roundly heralded. It promised protection two weeks after a single shot, didnt use the new messenger-RNA technology of the other brands or need special cold storage, making it attractive for people without easy access to pharmacies and health care facilities.

But in April 2021, a rare but serious blood clot issue was reported, production problems further delayed its rollout and finally, regulators largely recommended the other available vaccines. The vaccine never regained its footing.

More than a year later, most Americans considered up to date on their COVID vaccines have been given three shots an initial two and then a booster by Pfizer or Moderna. Those who started with Johnson & Johnsons single dose have been told to get just one more. King said he understands health officials are doing their best but wishes for more information and direction.

Other countries like Germany and France have called for J&Js shot to be followed by two other doses. The city of San Francisco has made third shots available, too, citing studies suggesting a J&J shot and single booster isnt good enough, and many doctors have urged a third dose. But federal health authorities have been silent on whether J&J plus a booster is as good as three Pfizer or Moderna shots, let alone four.

Asked whether the J&J shot and one booster is enough, the CDC simply referred to its current guidance of one Pfizer or Moderna booster, and two only for those with compromised immunity.

I think its a dereliction of duty by the CDC to not address the situation, said Dr. Michael Lin, an associate professor of neurobiology and bioengineering at Stanford University who strongly recommends a third dose for Johnson & Johnson vaccine recipients. The data are very clear. You need a third dose.

Evidence of waning immunity and the emergence of more contagious virus variants like delta and omicron spurred approval for booster doses last fall for all three authorized vaccines in the U.S. initially with no brand preference. Those vaccinated with Pfizer or Moderna were urged to get a booster five months after their second shot, and those who had J&J were told to get a booster after two months.

Then, in December, the Centers for Disease Control and Prevention recommended the Pfizer and Moderna vaccines over J&J for primary and booster shots, citing safety concerns.

Still, 16.8 million Americans received J&Js shot as their primary COVID-19 vaccine, about 8% of the U.S. total. In California, they include Gov. Gavin Newsom and Health and Human Services Secretary Dr. Mark Ghaly. Nearly 1.5 million got a J&J booster.

Assessing the efficacy of vaccines and boosters is challenging because its unclear how long their protection lasts as the virus mutates into new variants. Trials and studies based on the original strain or last summers delta are obsolete now with omicron and its more contagious sub-variant BA.2.

Unlike Pfizer and Moderna, Johnson & Johnson hasnt sought approval for a second booster. Instead, the company points to studies it says demonstrate the durability of protection from its vaccine. A March 17 study found J&J protection against the delta variant in the U.S. remained stable for six months.

An earlier Jan. 6 study found that while all three U.S. vaccines maintained protection against intensive-care hospitalizations, there was no increase in hospitalizations and only modest waning of protection against breakthrough infections six months after the J&J shot.

And a Dec. 30 study found the J&J booster was 85% effective in preventing hospitalization in South Africa when the omicron variant was prevalent.

But Dr. Bob Wachter, who chairs the medical department at UC San Francisco, said back in December that a J&J shot and Pfizer or Moderna booster offered only about the same protection as two primary Pfizer or Moderna shots.

Stanfords Dr. Lin points also to other studies he says show a J&J shot and booster are inferior to three Pfizer or Moderna shots. And San Francisco pointed to five studies in its Jan. 13 announcement that it would offer second boosters to J&J recipients who live or were vaccinated in the city.

Some who had the J&J shot havent waited for the governments guidance.

Aneela Mirchandani of San Francisco got a Pfizer booster in July after her April J&J shot, and another in December before she and her husband planned to travel.

I was hearing from doctors I know that despite the CDC, they were telling patients to boost it with a Pfizer or Moderna even though J&J was supposed to be a single shot, Mirchandani said. We were seeing delta shoot the numbers up, so we just got the second Pfizer and didnt worry about it too much.

Nearly a year after that first J&J shot, they remain COVID-free.

See the rest here:

COVID: Do J&J vaccine recipients need a second booster? Doctors and CDC have different opinions - Vallejo Times-Herald

Types of Covid Vaccines: How They Work, Effectiveness, & Side Effects – Healthline

March 29, 2022

Vaccines have been a critical tool in managing the COVID-19 pandemic. Researchers have been working on vaccines against the novel coronavirus, known as SARS-CoV-2, since it was first identified and characterized.

In fact, the World Health Organization (WHO) estimated that more than 200 COVID-19 vaccine candidates were in development in December of 2020. Since then, several vaccines have been authorized or approved for use around the world.

Generally speaking, there are four different types of COVID-19 vaccines that are being used throughout the world. Keep reading to learn what these are, how they work, and more.

As just mentioned, there are four types of COVID-19 vaccines that are being used around the world. These are:

The table below provides a brief summary of the different types of COVID-19 vaccines and the branded names that theyre associated with.

The mRNA vaccines work by teaching your body to make a protein from the novel coronavirus. This protein is called the spike protein. Normally, the virus uses it to attach to and enter cells.

These vaccines contain a molecule called mRNA thats surrounded by a protective lipid (fat) layer. The function of mRNA is to tell cells how to make proteins. Your cells use mRNA every day to make proteins that are vital for life.

Heres how the mRNA vaccines work:

There are currently two mRNA vaccines in use. These are the Pfizer-BioNTech and Moderna vaccines. Both of these vaccines are given as two doses. The Pfizer-BioNTech does are spaced out over 21 days (3 weeks). The Moderna doses are spaced out over 28 days (4 weeks).

Large-scale clinical trials found that both mRNA vaccines were very effective. Vaccine effectiveness was found to be 95 percent and 94.1 percent for the Pfizer and Moderna vaccines, in that order.

However, much has changed since these trials. Variants of the novel coronavirus have emerged, such as the highly infectious Omicron variant. The mRNA vaccines are less effective against these variants.

Because of the rise of variants as well as naturally decreasing immunity, public health organizations around the world have recommended booster doses.

As a result, research has focused on vaccine effectiveness in terms of variants and booster doses. Lets see what some of this research says.

A 2022 study examined the effectiveness of the Pfizer vaccine between November 2021 and January 2022. This studys findings about the effectiveness against the Omicron variant were as follows:

Another 2022 study looked at the effectiveness of the Moderna vaccine against the Omicron variant. This study reported the following:

Viral vector vaccines for COVID-19 use a modified virus to deliver instructions to your cells on how to make the spike protein. The modified virus is harmless and cant make copies of itself or cause disease.

The viral vector vaccines for COVID-19 all use an adenovirus vector. In nature, adenoviruses can cause cold- or flu-like symptoms.

Viral vector vaccines work in the following way:

There are a few examples of viral vector vaccines in use throughout the world. These include:

The large-scale clinical trials of the J&J vaccine found that a single vaccine dose was 66.9 percent effective for preventing moderate to severe or critical COVID-19.

Clinical trials of the AstraZeneca vaccine found that overall vaccine effectiveness after two doses was 70.4 percent.

The arrival of the Omicron variant has hit viral vector vaccines pretty hard. However, receiving a booster with an mRNA vaccine can help.

One of the 2022 studies discussed earlier also looked at the effectiveness of the AstraZeneca vaccine against the Omicron variant. This studys findings were as follows:

Protein subunit vaccines are pretty straightforward. They contain a purified protein from a virus that the immune system can see and respond to. In the case of the novel coronavirus, this protein is the spike protein.

Protein subunit vaccines work in the following way:

There are various protein subunit vaccines in development. One that you may have heard of is the Novavax vaccine, which is given in two doses spaced 21 days (3 weeks) apart.

The spike protein in the Novavax vaccine is made in cells in a laboratory and is purified before being stuck onto a tiny, round particle called a nanoparticle. This design imitates the shape of the novel coronavirus and also helps to group many spike proteins together so that the immune system can see them.

A large-scale clinical trial of the Novavax vaccine found that its effectiveness was 90.4 percent.

However, this trial was performed in early 2021, before the arrival of the Delta and Omicron variants. Detailed data on the Novavax vaccines effectiveness against these variants havent been published yet.

So far, Novavax has released a statement based off of early data that antibodies from the first two-dose vaccine series have some effectiveness against the Omicron variant. Protection also increased after a booster dose.

The last type of COVID-19 vaccines are whole virus vaccines. These vaccines contain whole virus particles, known as virions, of SARS-CoV-2, the virus that causes COVID-19.

The only whole virus vaccines that are in use are inactivated. In an inactivated vaccine, the virus has been treated so that it remains whole but cant cause disease. This is typically accomplished by using chemicals or heat.

An inactivated whole virus vaccine works in the following way:

Two examples of inactivated whole virus vaccines are the Sinovac and Sinopharm vaccines.

A 2021 study of the Sinovac vaccine, called CoronaVac, found that vaccine was only 46.8 percent effective against symptomatic SARS-CoV-2 infection after the second vaccine dose.

The Omicron variant has greatly impacted the effectiveness of the available inactivated vaccines.

Overall, researchers are finding that these vaccines provide little to no protection against this variant. However, boosters with another type of vaccine may help to restore this protection.

Before being used on a wide scale, all vaccines need to be shown to be both safe and effective in large-scale clinical trials.

In the United States, the Food and Drug Administration (FDA) reviews the data from these trials before approving the vaccine or issuing an emergency use authorization.

Generally speaking, some of the most common side effects of COVID-19 vaccines are:

These side effects typically come on within a day of receiving a vaccine dose. They only last a few days before going away on their own.

If you have side effects such as fatigue, fever, and muscle pain, you may feel as if the vaccine is making you sick. However, these symptoms are completely normal and are actually a sign that your body is creating an immune response to the vaccine.

There are some people who shouldnt receive a COVID-19 vaccine. This is called a contraindication to vaccination. For the vaccines that are currently in use in the United States, the only contraindications to COVID-19 vaccines are:

In rare situations, mRNA vaccines can lead to myocarditis, or inflammation of the heart muscle. The Centers for Disease Control and Prevention (CDC) notes that this is more common:

According to a 2021 study of 139 teens and young adults with suspected myocarditis after vaccination, the condition was typically mild and resolved quickly when treatment was given.

Additionally, a 2022 study found that a person was more likely to develop myocarditis after contracting SARS-CoV-2 than after receiving a COVID-19 vaccine.

Although very rare, serious side effects such as TTS and Guillain-Barr syndrome (GBS) have been reported after vaccination with viral vector vaccines such as the J&J and AstraZeneca vaccines.

Based off of an updated risk-benefit analysis, the CDC is now recommending that people receive an mRNA vaccine over the J&J vaccine. This recommendation was made based on the fact that the J&J vaccine:

Similarly, the United Kingdom offers alternatives to the AstraZeneca vaccine in individuals under the age of 40. These alternatives were offered because people in this age group, particularly people assigned female at birth, are at a higher risk of TTS.

There are several different types of COVID-19 vaccines. These vaccines all work in different ways to prepare your immune system to respond to the novel coronavirus, should you be exposed to it.

Before being widely used, vaccines must go through a rigorous clinical trial process to assess their safety and effectiveness. As such, vaccines that have been authorized or approved have been shown to be safe and effective.

To increase your protection against COVID-19, its important to stay up to date on your COVID-19 vaccinations. Never hesitate to talk with a doctor or other healthcare professional if you have any concerns or questions about vaccination.

Read more:

Types of Covid Vaccines: How They Work, Effectiveness, & Side Effects - Healthline

Page 262«..1020..261262263264..270280..»